Axavive has introduced a plant-based skin support supplement featuring Astragaloside IV, a compound derived from Astragalus membranaceus, aimed at promoting collagen wellness, antioxidant defense, and skin hydration. The formula includes six botanical ingredients designed to support skin structure, elasticity, and cellular repair pathways. While ingredient-level research supports the potential benefits of Astragaloside IV, no clinical trials on the finished product exist, and the supplement is not FDA-approved to treat or prevent aging. Axavive is manufactured in the USA under GMP standards, sold exclusively online starting at $158, and comes with a 90-day money-back guarantee for customer assurance.
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a ...
Levi & Korsinsky has started an investigation into Prestige Consumer Healthcare following the company's failure to meet its Q4 and full-year financial projections, including adjusted gross margin, free cash flow, and adjusted EPS. Additionally, Prest...
Levi & Korsinsky has started an investigation into TriSalus Life Sciences following the company's Q1 2026 revenue of $8.9 million, which missed Wall Street's $9.4 million estimate. The company also lowered its full-year 2026 revenue forecast to $54 m...
Bitcoin whale traders have shifted aggressively toward short positions, reflecting growing defensive sentiment amid weakening broader crypto momentum. Large speculative wallets reduced altcoin exposure and increased leveraged Bitcoin shorts, with one...
Figma has achieved a 46% year-over-year revenue growth and improved its net dollar retention to 139%, showing resilience against fears of AI disruption. The company is transitioning to a usage-based pricing model and benefiting from AI trends, which ...
